CAR-T Cancer Approach Has Surprising Success in Multiple Myeloma – NBCNews.com
NBCNews.com |
CAR–T Cancer Approach Has Surprising Success in Multiple Myeloma
NBCNews.com Doctors are reporting unprecedented success from a new cell and gene therapy for multiple myeloma, a blood cancer that’s on the rise. Although it’s early and the study is small — 35 people — every patient responded and all but two were in some level … Gene-Based Therapy May Thwart a Tough Blood CancerDoctors Lounge A first: All respond to gene therapy in a blood cancer studyMinneapolis Star Tribune |
NBCNews.com |
CAR–T Cancer Approach Has Surprising Success in Multiple Myeloma
NBCNews.com Doctors are reporting unprecedented success from a new cell and gene therapy for multiple myeloma, a blood cancer that’s on the rise. Although it’s early and the study is small — 35 people — every patient responded and all but two were in some level … CAR T- Cell Therapy Could Be A Promising Treatment For Multiple Myeloma CancerScience World Report Therapy Shows High Remission Rates in Multiple MyelomaCuretoday.com Gene-Based Therapy That Reprograms Immune Cells Offers Hope For Multiple Myeloma CureTech Times News-Medical.net –ABC News –Real Fact 24 all 18 news articles » |
Chicago Sun-Times |
Gene therapy to fight blood cancer finds unprecedented success
Chicago Sun-Times Doctors told a medical conference in Chicago Monday they’ve had unprecedented success with a new cell and gene therapy for multiple myeloma, a blood cancer that’s on the rise. Though it’s still early and the study was small — just 35 people — every … A first: All respond to gene therapy in a blood cancer studyABC News |
|
Researchers Seeking Biomarkers for Immune-Related Adverse Events During Immunotherapy
GenomeWeb CHICAGO (GenomeWeb) – Researchers are on the hunt for germline or somatic risk variants that might serve as markers for predicting immune-related adverse events (irAEs) in individuals treated with immune checkpoint blockade-based immunotherapy. |
|
Researchers Seeking Biomarkers for Immune-Related Adverse Events During Immunotherapy
GenomeWeb CHICAGO (GenomeWeb) – Researchers are on the hunt for germline or somatic risk variants that might serve as markers for predicting immune-related adverse events (irAEs) in individuals treated with immune checkpoint blockade-based immunotherapy. |